ArticleAntonie van Leeuwenhoek2026
A proteome-driven strategy to discover novel therapeutic targets in Orientia tsutsugamushi.
Article in Antonie van Leeuwenhoek, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Orientia tsutsugamushi (OT), an obligate intracellular Gram-negative bacterium of the Rickettsiaceae family, causes scrub typhus (ST), a re-emerging vector-borne infectious disease with significant morbidity and mortality in South and Southeast Asia. Despite its widespread prevalence and mortality rates reaching up to 30% in untreated individuals, no effective vaccines or targeted therapeutics are currently available.Compounding these challenges are limitations in existing diagnostic methods, increasing antibiotic resistance, and complex interactions among host, pathogen, and vector. To address these critical gaps, this study conducted a comprehensive genome-wide comparative analysis across 23 OT strains, including UT 76, Karp, Kato, Gilliam, and Wuj/2014, using an in-house R-based computational pipeline. This analysis identified a conserved core genome of 744 genes, of which 19 are unique and pathogen- specific proteins. Subcellular localisation analyses revealed that nine of these proteins are membrane- associated, highlighting their potential accessibility to therapeutic agents. Additionally, proteins were prioritised through an integrative analysis that incorporates protein- protein interaction networks, druggability assessments, and antigenicity profiling. Six key proteins- dnaK, fusA, fabG, infB, nuoN and fabI were identified based on their essential roles in pathogen- specific pathways. These proteins are involved in membrane transport, transcription regulation, and biosynthesis, making them promising drug targets. Notably, this study employs in silico methodologies to overcome limitations inherent to traditional wet-lab approaches. Computational strategies are cost-effective for identifying conserved targets and supporting hypothesis- driven drug discovery. The findings presented here not only reveal previously uncharacterized therapeutic targets but also establish a genomic framework to improve diagnostic accuracy and guide future drug development against ST.
Indexed as
Identifiers
42365542What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.